Promotive Communications

Lab Focus February March 2017

Laboratory Focus is Canada's leading editorial-based lab publication. Providing readers with the latest technology updates through application and tech notes, as well as covering new products and trends in laboratories across Canada.

Issue link: http://laboratoryfocus.uberflip.com/i/802185

Contents of this Issue

Navigation

Page 0 of 19

R&D News ......................... 1 Appointments .................... 6 Pharma Notes .................... 7 New Products .................. 15 Calendar .......................... 17 App Reviews ..................... 18 P h a r m a c e u t i c a l c l i n i c a l c h e m i c a l f o o d e n v i r o n m e n t w w w . l a b o r a t o r y f o c u s . c a february/march 2017 volume 21, number 1 Publications Mail Registration Number: 40052410 ottawa researchers kill brain cancer in mice with combination immunotheraPies OTTAWA, ON – A team of research- ers from the Children's Hospital of Eastern Ontario (CHEO) have pub- lished new data in Nature Commu- nications showing that a promising combination of immunotherapies can deliver a one-two punch to brain cancer tumours in mice. As part of their study, Drs. Eric Lacasse, Shawn Beug and Robert Korneluk found that a combination of drugs known as SMAC Mimetics and immune checkpoint inhibitors (ICIs) were able to amplify the kill rates of cancer tumour cells. At the same time they discovered a new mechanism by which the combina- tion promotes long-term immunity against glioblastoma tumours. The combination therapy also proved to be highly effective against breast cancer and multiple myeloma. "These findings represent a sig- nificant evolution in our research and the field of immunotherapy... we are the first in the world to show the synergistic tumour-killing im- pact of combining SMAC Mimetics can improved technology for Glycosylation analysis expedite biosimilar development Page 8 automation: a more reliable and scalable way to process samples in the biopharmaceutical lab Page 13 with immune checkpoint inhibitors for glioblastoma," said Dr. Korn- eluk, a professor at the University of Ottawa and senior scientist at the CHEO Research Institute. "You could say it takes two to tango, that it takes a combination strategy to impact cancer cure rates," he adds. In 2014, a team of scientists led by Dr. Korneluk discovered that combining SMAC Mimetics with immune stimulators, or live virus therapies, had a synergistic or am- plified tumour-killing effect that was greater than either agent on its own. These latest findings show that SMAC Mimetics also have a powerful synergistic effect with ICIs, which are relatively new drugs that are showing great promise in the clinic. As part of this latest study, SMAC Mimetics known as LCL161 and Birinapant were combined with ICI antibodies targeting PD-1 and CTLA-4 immune checkpoints. Dr. Lacasse, a scientist at the CHEO Research Institute, adds "Two drug companies have initiated human clinical trials this year to assess the impact of this combina- tion of SMAC Mimetics and ICIs on patients with a variety of cancers." Although it could be years before any clinical trials begin for adults or children with the deadly brain cancer, glioblastoma, he says the research team is looking forward to seeing how scientific evidence from these experimental treat- ments will impact future research initiatives. "It's an exciting, explor- atory field and we hope we've hit a home run," he said. "This research heightens our understanding of the mechanics behind this double-whammy ef- fect, which both enhances the immune response and weakens tumour cells to immune attack," commented Beug, lead author of the 2014 and 2017 papers. "We're hoping that more oncologists and biotech companies test out this combination in clinical trials as we continue to decipher how SMAC Mimetics encourage the immune system to kill cancer cells." The research was funded by the Canadian Cancer Society Re- search Institute, Brain Canada (with financial support from Health Canada through the Canada Brain Research Fund) and the Canadian Institutes of Health Research. In addition, the work was supported by donations to the Ottawa Re- gional Cancer Foundation, the Kiwanis Medical Foundation and the CHEO Foundation. To see this story online visit http://laboratoryfocus.ca/ottawa- researchers-kill-brain-cancer-in- mice-with-combination-immuno- therapies/ (L to R) Drs. Eric Lacasse, Shawn Beug and Robert Korneluk

Articles in this issue

Links on this page

view archives of Promotive Communications - Lab Focus February March 2017